Myeloproliferative Neoplasm Quality of Life

~ International Study Group ~

For MPN-QOL Investigators

For MPN Healthcare Providers

Decrease Font Size
Increase Font Size


We would like to announce two new upcoming posters to be presented at the 17th Annual European Hematological Association in Amsterdam, Netherlands on June 14-17, 2012. The first, written by Geyer et. al., entitled “Ruxolitinib in Clinical Practice for Therapy of Myelofibrosis: Single USA Center Experience After FDA Approval” details the clinical experience so far with the first JAK2 inhibitor to obtain FDA approval for the treatment of symptomatic myelofibrosis. The second poster, written by Scherber et. al. entitled “Conventional Therapeutic Options have Limited Impact on MPN Symptoms: Insights from a Prospective Analysis of the MPN-SAF TSS” discusses the impact of traditional MPN therapies on MPN symptom burden from a sample of over 1,400 MPN patients worldwide.

Last Updated Tuesday, September 25, 2018 - 04:12 AM.